Tag: biotech
-
Foundry Row’s Biotech Growth Is Reshaping the City’s Bottom Line, Budget Office Finds
A budget office report projects nearly $11 million in additional city tax revenue driven by Foundry Row’s biotech expansion, prompting a debate over whether to save the windfall or spend it on transit, housing and workforce priorities.
-
Kestrel Biologics Hits Its Hiring Target, With Help It Didn’t Expect to Need
Kestrel Biologics says it has nearly doubled its Bellwater workforce, hitting its two-year hiring target partly by absorbing technicians laid off by rival Ridgeline Therapeutics.
-
Biotech Jobs on Foundry Row Have Doubled in Five Years, City-Commissioned Report Finds
A new city-commissioned report finds Foundry Row’s biotech cluster has roughly doubled its workforce in five years, though hiring growth has slowed amid a persistent shortage of trained technicians.
-
$3.2 Million Federal Grant Expands Tan’s Kincaid Gene-Therapy Lab
Dr. Wei-Lin Tan’s Kincaid gene-therapy lab won a $3.2 million federal research grant, expanding her team even as economists warn it adds to the region’s biotech skills gap.
-
Kestrel Biologics Weighs West Bellwater for New Manufacturing Site
Kestrel Biologics is scouting sites for a second manufacturing facility, including in West Bellwater, as the Foundry Row biotech firm outgrows its current lab and production space.
-
Gene-Therapy Trial Clears Early Safety Hurdle for Kestrel Biologics
Kestrel Biologics says its lead gene-therapy candidate has cleared an early safety milestone in its Phase 1 trial, a result executives call validation for the Foundry Row biotech firm’s $64 million funding round.
-
Board Votes 9-1 to Extend Castellano’s Contract by a Decade
Bellwater State’s board voted 9-1 to extend Chancellor Eleanor Castellano’s contract through the next decade, with one trustee objecting to the absence of performance benchmarks.
-
Debate Over Foundry Row Building Heights Pits Biotech Demand Against Displacement Fears
A proposal to cap new Foundry Row towers at 12 stories has split biotech employers seeking room to grow from tenant advocates who say unchecked height will accelerate displacement, with a council vote expected in coming weeks.
-
Ridgeline Therapeutics Closes $38 Million Round to Compete for Biotech Talent
Ridgeline Therapeutics has closed a $38 million funding round it says is aimed at competing with rival Kestrel Biologics for Bellwater’s limited pool of biotech talent.
-
Whitfield Warns of $18.6 Million Gap as Budget Season Begins
City Manager Marcus Whitfield opened budget season by warning the city faces an $18.6 million gap next year, as rising pension and health care costs outpace growing biotech-sector tax revenue.